EGFR blockade with ZD1839 (IRESSA) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinomaSOLOMON, Benjamin; HAGEKYRIAKOU, Jim; TRIVETT, Melanie K et al.International journal of radiation oncology, biology, physics. 2003, Vol 55, Num 3, pp 713-723, issn 0360-3016, 11 p.Article

Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cellsRODRIGUES, Sylvie; ATTOUB, Samir; GESPACH, Christian et al.Oncogene (Basingstoke). 2003, Vol 22, Num 29, pp 4488-4497, issn 0950-9232, 10 p.Article

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumorsOCHS, Judith S.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 3, pp 941-949, issn 0360-3016, 9 p.Conference Paper

Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cellsCHEN, Yunhao; LOW, Teck-Yew; BIN LI et al.Proteomics (Weinheim. Print). 2007, Vol 7, Num 14, pp 2384-2397, issn 1615-9853, 14 p.Article

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumorsNAKAGAWA, K; TAMURA, T; FUKUOKA, M et al.Annals of oncology. 2003, Vol 14, Num 6, pp 922-930, issn 0923-7534, 9 p.Article

Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancerRECK, Martin; GATZEMEIER, Ulrich.Respiratory medicine. 2005, Vol 99, Num 3, pp 298-307, issn 0954-6111, 10 p.Article

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibitionYANO, Seiichi; KONDO, Kaoru; YAMAGUCHI, Motonori et al.Anticancer research. 2003, Vol 23, Num 5A, pp 3639-3650, issn 0250-7005, 12 p.Article

Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. CommentaryFUJIWARA, Keiichi; KIURA, Katsuyuki; UEOKA, Hiroshi et al.Lung cancer. 2003, Vol 40, Num 1, pp 73-78, issn 0169-5002, 6 p.Article

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary culturesVICENTINI, Carlo; FESTUCCIA, Claudio; GRAVINA, Giovanni Luca et al.Journal of cancer research and clinical oncology. 2003, Vol 129, Num 3, pp 165-174, issn 0171-5216, 10 p.Article

Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulationDAVIS, Courtney; ABRAHAM, John.Sociology of health & illness (Print). 2011, Vol 33, Num 5, pp 731-747, issn 0141-9889, 17 p.Article

Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatinXU, Jian-Ming; AZZARITI, Amalia; SEVERINO, Montemuro et al.Biochemical pharmacology. 2003, Vol 66, Num 4, pp 551-563, issn 0006-2952, 13 p.Article

Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patientROGGERO, Enrico; GIANCARLA, Busi; ANTONELLA, Palumbo et al.Journal of neuro-oncology. 2005, Vol 71, Num 3, pp 277-280, issn 0167-594X, 4 p.Article

Reacción cutánea secundaria a tratamiento con Iressa (ZD1839) = Skin reaction secondary to treatment with Iressa (Dd1839)ISARRIA, Maria José; ALONSO, Ignacio; SEGURADO, Agustina et al.Actas dermo-sifiliográficas (Ed. impresa). 2004, Vol 95, Num 7, pp 459-461, issn 0001-7310, 3 p.Article

The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell linesXU, Jian-Ming; AZZARITI, Amalia; COLUCCI, Giuseppe et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 6, pp 442-448, issn 0344-5704, 7 p.Article

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugsCIARDIELLO, F; TORTORA, Giampaolo.European journal of cancer (1990). 2003, Vol 39, Num 10, pp 1348-1354, issn 0959-8049, 7 p.Article

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?WILSON, C. G; O'MAHONY, B; CONNOLLY, S. M et al.International journal of pharmaceutics (Print). 2009, Vol 376, Num 1-2, pp 7-12, issn 0378-5173, 6 p.Article

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancerARGIRIS, Athanassios; MITTAL, Namrata.Lung cancer. 2004, Vol 43, Num 3, pp 317-322, issn 0169-5002, 6 p.Article

Pharmacological background of EGFR targetingCASTILLO, L; ETIENNE-GRIMALDI, M. C; FISCHEL, J. L et al.Annals of oncology. 2004, Vol 15, Num 7, pp 1007-1012, issn 0923-7534, 6 p.Article

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('iressa', ZD1839) in phase I and II clinical trialsTULLO, A. B; ESMAELI, B; MURRAY, P. I et al.Eye (London. 1987). 2005, Vol 19, Num 7, pp 729-738, issn 0950-222X, 10 p.Article

Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergyAOE, Keisuke; HIRAKI, Akio; MURAKAMI, Tomoyuki et al.Anticancer research. 2005, Vol 25, Num 1B, pp 415-418, issn 0250-7005, 4 p.Article

Protein kinase inhibitors : Structural insights into selectivity : Target specificity of effective anticancer therapeuticsTHAIMATTAM, Ram; BANERJEE, Rahul; MIGLANI, Rajni et al.Current pharmaceutical design. 2007, Vol 13, Num 27, pp 2751-2765, issn 1381-6128, 15 p.Article

EGFR regulates the side population in head and neck squamous cell carcinomaCHEN, Jocelyn S; PARDO, Francisco S; WANG-RODRIGUEZ, Jessica et al.The Laryngoscope. 2006, Vol 116, Num 3, pp 401-406, issn 0023-852X, 6 p.Article

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinomaJERMANN, Monika; STAHEL, Rolf A; PLESS, Miklos et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 533-539, issn 0344-5704, 7 p.Article

Benefit in lung function improvement and side-effect profile of long-term responders : An analysis of 14 NSCLC patients treated for at least 9 months with gefitinibRECK, Martin; GATZEMEIER, Ulrich.Lung cancer. 2005, Vol 50, Num 1, pp 107-114, issn 0169-5002, 8 p.Article

ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyWAKELING, Alan E; GUY, Simon P; WOODBURN, Jim R et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5749-5754, issn 0008-5472, 6 p.Article